- •This multi-center study is the largest series on the use of the biosynthetic glutaraldehyde denatured ovine collagen graft (Omniflow II®) in an infected environment.
- •It confirms the plausibility of using the Omniflow II® bioprosthetic graft in a septic field, with excellent procedural success rates and encouraging freedom from major amputation, reinfection and secondary patency rates given the disease severity of these patients.
- •As such, the Omniflow II represents an acceptable vascular substitute in the absence of an autologous vein.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Major groin complications following the use of synthetic grafts.Eur J Vasc Endovasc Surg. 2007; 34: 188-190https://doi.org/10.1016/j.ejvs.2007.03.012
- Medical treatment of prosthetic vascular graft infections: review of the literature and proposals of a Working Group.Int J Antimicrob Agents. 2015; 46: 254-265https://doi.org/10.1016/j.ijantimicag.2015.04.014
- Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus.J Antimicrob Chemother. 2005; 56: 996-999https://doi.org/10.1093/jac/dki382
- Diagnosis and management of staphylococcal infections of vascular grafts and stents.Intern Med J. 2005; 35: S72-S78https://doi.org/10.1111/j.1444-0903.2005.00981.x
- Editor’s choice – European society for vascular surgery (ESVS) 2020 clinical practice guidelines on the management of vascular graft and endograft infections.Eur J Vasc Endovasc Surg. 2020; 59: 339-384https://doi.org/10.1016/j.ejvs.2019.10.016
- Conservative treatment of vascular prosthetic graft infection is associated with high mortality.Am J Surg. 2010; 200: 47-52https://doi.org/10.1016/j.amjsurg.2009.05.018
- Diagnosis and management of prosthetic vascular graft infections.Med Mal Infect. 2012; 42: 102-109https://doi.org/10.1016/j.medmal.2012.01.003
- A 10-year experience of using femoro-popliteal vein for re-vascularisation in graft and arterial infections.Eur J Vasc Endovasc Surg. 2009; 38: 172-179https://doi.org/10.1016/j.ejvs.2009.03.009
- Bypass in the absence of ipsilateral greater saphenous vein: safety and superiority of the contralateral greater saphenous vein.J Vasc Surg. 2002; 35: 1085-1092
- Cryopreserved cadaveric arterial allograft for arterial reconstruction in patients with prosthetic infection.Eur J Vasc Endovasc Surg. 2017; 54: 636-644https://doi.org/10.1016/j.ejvs.2017.07.016
- Cryopreserved saphenous vein as a last-ditch conduit for limb salvage.J Vasc Surg. 2017; 66: 844-849https://doi.org/10.1016/j.jvs.2017.03.415
- Outcomes of cold-stored venous allograft for below-knee bypasses in patients with critical limb ischemia.J Vasc Surg. 2015; 62: 974-983https://doi.org/10.1016/j.jvs.2015.04.437
- Microbial spectrum and primary resistance to rifampicin in infectious complications in vascular surgery: limits to the use of rifampicin-bonded prosthetic grafts.Angiology. 2010; 61: 423-426https://doi.org/10.1177/0003319709360029
- In situ revascularisation for femoropopliteal graft infection: ten years of experience with silver grafts.Vascular. 2014; 22: 323-327https://doi.org/10.1177/1708538113504399
- Glutaraldehyde-tanned ovine collagen conduits as vascular xenografts in dogs: a preliminary report.Arch Surg. 1980; 115: 967-969https://doi.org/10.1001/archsurg.1980.01380080057011
- Structural stability of long-term implants of a collagen-based vascular prosthesis.J Long Term Eff Med Implants. 1991; 1: 107-119
- Analysis of 274 Omniflow vascular prostheses implanted over an eight-year period.Aust N Z J Surg. 1997; 67: 637-639
- Biosynthetic grafts to replace infected prosthetic vascular bypasses: a single-center experience.Surg Infect (Larchmt). 2017; 18: 202-205https://doi.org/10.1089/sur.2016.203
- Crural bypass for critical lower limb ischemia with Omniflow II prosthesis.Thorac Cardiovasc Surg. 2016; 64: 311-315https://doi.org/10.1055/s-0035-1560039
- Mid- and long-term results after replacement of infected peripheral vascular prosthetic grafts with biosynthetic collagen prosthesis.J Cardiovasc Surg (Torino). 2014; 55: 693-698
- Diagnosis of aortic graft infection: a case definition by the management of aortic graft infection collaboration (MAGIC).Eur J Vasc Endovasc Surg. 2016; 52: 758-763https://doi.org/10.1016/j.ejvs.2016.09.007
- Retrospective study comparing WBC scan and 18F-FDG PET/CT in patients with suspected prosthetic vascular graft infection.Eur J Vasc Endovasc Surg. 2019; 57: 876-884
- Continuous irrigation as a therapeutic option for graft infections of the groin.World J Surg. 2014; 38: 2589-2596https://doi.org/10.1007/s00268-014-2650-8
- Treatment of aortic graft infection by in situ reconstruction with Omniflow II biosynthetic prosthesis.Vascular. 2016; 24: 561-566https://doi.org/10.1177/1708538115621195
- Cryopreserved arterial allograft reconstruction for infected peripheral bypass.Ann Vasc Surg. 2010; 24: 994-999https://doi.org/10.1016/j.avsg.2010.01.017
- Early results after peripheral vascular replacement with biosynthetic collagen prosthesis in cases of graft infection.Zentralbl Chir. 2014; 139: 546-551https://doi.org/10.1055/s-0032-1327968
- Arterial reconstruction with cryopreserved human allografts in the setting of infection: a single-center experience with midterm follow-up.J Vasc Surg. 2009; 49: 660-666https://doi.org/10.1016/j.jvs.2008.10.026
- Which prosthesis is more resistant to vascular graft infection: polytetrafluoroethylene or Omniflow II biosynthetic grafts?.Surg Today. 2016; 46: 363-370https://doi.org/10.1007/s00595-015-1141-3
- Susceptibility of vascular implants to colonization in vitro by Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis and Pseudomonas aeruginosa.Pol J Microbiol. 2017; 66: 125-129https://doi.org/10.5604/17331331.1235001
- In vivo assessment of neovascularization and incorporation of prosthetic vascular biografts.Thorac Cardiovasc Surg. 1992; 40: 19-25https://doi.org/10.1055/s-2007-1020105
Publication stageIn Press Journal Pre-Proof
Key Findings: The use of the Omniflow II® bioprosthetic graft for infra-inguinal revascularization in the context of sepsis in 29 patients showed excellent procedural success rates and encouraging freedom from major amputation, reinfection and secondary patency rates given the disease severity of these patients.
Take home Message: The Omniflow II® bioprosthetic graft represents an acceptable vascular substitute for infra-inguinal revascularization in the context of sepsis in the absence of an autologous vein.
Table of Contents Summary: This retrospective observational study analyzed the results of infra-inguinal revascularization with the Omniflow® bioprosthetic graft in the context of sepsis in 29 patients. It provided acceptable freedom from major amputation and reinfection in the absence of an autologous vein considering the seriousness of this pathology.
Declaration of Conflicting Interests: The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.